We do not display all the achieved goals on the graph, you can get detailed information about the achieved goals in the corresponding section on this page
Stock ticker: | LLY |
Name: | ELI LILLY AND COMPANY |
Sector: | Healthcare |
Investing Risk: | — |
Forecast length: | — |
Accuracy: | — |
Average profit per target: | — |
Signal Date | Signal Price | Date Reached | Price Reached | Profit | Direction |
---|---|---|---|---|---|
2022-04-29 | 283.64 $ | 2022-11-30 | 363.7 $ | 28.23% | |
2022-05-06 | 288.27 $ | 2022-11-30 | 363.7 $ | 26.17% | |
2022-05-16 | 291.66 $ | 2022-11-08 | 358.37 $ | 22.87% | |
2022-06-02 | 294.63 $ | 2023-04-21 | 378.8 $ | 28.57% | |
2022-06-10 | 289.35 $ | 2022-12-02 | 367.31 $ | 26.94% | |
2022-07-01 | 316.33 $ | 2023-05-01 | 399.03 $ | 26.14% | |
2022-07-08 | 321.94 $ | 2023-05-03 | 423.98 $ | 31.69% | |
2022-07-15 | 323.05 $ | 2023-05-03 | 423.98 $ | 31.24% | |
2022-07-22 | 320.27 $ | 2023-05-01 | 399.03 $ | 24.59% | |
2022-08-04 | 297.9 $ | 2023-05-03 | 423.98 $ | 42.32% | |
2022-11-25 | 357.99 $ | 2023-05-03 | 423.98 $ | 18.44% | |
2022-11-28 | 358.49 $ | 2023-05-03 | 423.98 $ | 18.27% | |
2022-11-29 | 356.71 $ | 2023-05-03 | 423.98 $ | 18.86% | |
2022-12-09 | 353.81 $ | 2023-05-03 | 423.98 $ | 19.83% | |
2022-12-12 | 359.95 $ | 2023-05-03 | 423.98 $ | 17.79% | |
2022-12-13 | 351.53 $ | 2023-05-03 | 423.98 $ | 20.61% | |
2022-12-14 | 356.27 $ | 2023-05-03 | 423.98 $ | 19.01% | |
2022-12-15 | 352.85 $ | 2023-05-03 | 423.98 $ | 20.16% | |
2022-12-16 | 352.71 $ | 2023-05-03 | 423.98 $ | 20.21% | |
2022-12-20 | 352.49 $ | 2023-05-03 | 423.98 $ | 20.28% | |
2022-12-22 | 358.04 $ | 2023-05-03 | 423.98 $ | 18.42% | |
2022-12-27 | 357.62 $ | 2023-05-03 | 423.98 $ | 18.56% | |
2022-12-28 | 357.96 $ | 2023-05-03 | 423.98 $ | 18.45% | |
2022-12-29 | 359.72 $ | 2023-05-03 | 423.98 $ | 17.86% | |
2022-12-30 | 358.56 $ | 2023-05-03 | 423.98 $ | 18.24% | |
2023-01-03 | 357.73 $ | 2023-05-03 | 423.98 $ | 18.52% | |
2023-01-04 | 355.88 $ | 2023-05-03 | 423.98 $ | 19.14% | |
2023-01-05 | 351.78 $ | 2023-05-03 | 423.98 $ | 20.52% | |
2023-01-06 | 355.72 $ | 2023-05-03 | 423.98 $ | 19.19% | |
2023-01-09 | 342.87 $ | 2023-05-03 | 423.98 $ | 23.66% | |
2023-01-10 | 345.73 $ | 2023-05-03 | 423.98 $ | 22.63% | |
2023-01-11 | 353.24 $ | 2023-05-03 | 423.98 $ | 20.03% | |
2023-02-03 | 332.34 $ | 2023-05-08 | 425.49 $ | 28.03% | |
2023-02-06 | 330.94 $ | 2023-05-03 | 423.98 $ | 28.11% | |
2023-02-07 | 332.92 $ | 2023-05-03 | 423.98 $ | 27.35% | |
2023-02-08 | 333.95 $ | 2023-05-10 | 428.63 $ | 28.35% | |
2023-02-09 | 334.99 $ | 2023-05-10 | 428.63 $ | 27.95% | |
2023-02-13 | 343.43 $ | 2023-05-10 | 428.63 $ | 24.81% | |
2023-02-14 | 341.75 $ | 2023-05-16 | 430.47 $ | 25.96% | |
2023-02-15 | 329.41 $ | 2023-05-16 | 430.47 $ | 30.68% | |
2023-02-17 | 322.91 $ | 2023-05-03 | 423.98 $ | 31.3% | |
2023-02-21 | 322.03 $ | 2023-05-03 | 423.98 $ | 31.66% | |
2023-02-22 | 323.57 $ | 2023-05-08 | 425.49 $ | 31.5% | |
2023-02-24 | 316.26 $ | 2023-05-03 | 423.98 $ | 34.06% | |
2023-02-28 | 306.02 $ | 2023-05-08 | 425.49 $ | 39.04% | |
2023-03-01 | 308.92 $ | 2023-05-10 | 428.63 $ | 38.75% | |
2023-03-02 | 309.78 $ | 2023-05-03 | 423.98 $ | 36.86% | |
2023-03-16 | 324.02 $ | 2023-05-03 | 423.98 $ | 30.85% | |
2023-03-21 | 325.54 $ | 2023-05-19 | 436.12 $ | 33.96% | |
2023-03-22 | 325.44 $ | 2023-05-19 | 436.12 $ | 34.01% | |
2023-03-24 | 330.51 $ | 2023-05-01 | 399.03 $ | 20.73% | |
2023-04-14 | 368.46 $ | 2023-08-08 | 514.21 $ | 39.56% | |
2023-04-17 | 366.12 $ | 2023-08-08 | 514.21 $ | 40.45% | |
2023-04-19 | 364.28 $ | 2023-06-30 | 462.34 $ | 26.92% | |
2023-04-20 | 368.54 $ | 2023-06-30 | 462.34 $ | 25.45% | |
2023-04-24 | 376.94 $ | 2023-08-08 | 514.21 $ | 36.42% | |
2023-04-25 | 378.41 $ | 2023-08-08 | 514.21 $ | 35.89% | |
2023-04-26 | 369.98 $ | 2023-08-08 | 514.21 $ | 38.98% | |
2023-04-27 | 383.82 $ | 2023-08-08 | 514.21 $ | 33.97% | |
2023-04-28 | 389.24 $ | 2023-08-08 | 514.21 $ | 32.11% | |
2023-05-01 | 399.03 $ | 2023-08-08 | 514.21 $ | 28.87% | |
2023-05-02 | 397.44 $ | 2023-08-08 | 514.21 $ | 29.38% | |
2023-05-04 | 421.28 $ | 2023-08-08 | 514.21 $ | 22.06% | |
2023-05-09 | 421.22 $ | 2023-08-08 | 514.21 $ | 22.08% | |
2023-05-10 | 428.63 $ | 2023-08-08 | 514.21 $ | 19.97% | |
2023-05-11 | 428.27 $ | 2023-08-08 | 514.21 $ | 20.07% | |
2023-05-12 | 428.28 $ | 2023-08-08 | 514.21 $ | 20.07% | |
2023-05-19 | 436.12 $ | 2023-08-08 | 514.21 $ | 17.91% | |
2023-05-24 | 419.74 $ | 2023-08-08 | 514.21 $ | 22.51% | |
2023-06-01 | 430.31 $ | 2023-08-08 | 514.21 $ | 19.5% | |
2023-06-09 | 439.72 $ | 2023-08-28 | 547.25 $ | 24.45% | |
2023-06-13 | 439.41 $ | 2023-08-14 | 531.52 $ | 20.96% | |
2023-08-14 | 531.52 $ | 2024-02-01 | 653.68 $ | 22.98% | |
2023-10-27 | 553.48 $ | 2024-02-01 | 653.68 $ | 18.1% | |
2023-10-31 | 547.26 $ | 2024-02-01 | 653.68 $ | 19.45% | |
2023-11-01 | 547.78 $ | 2024-02-01 | 653.68 $ | 19.33% | |
2023-11-14 | 604.58 $ | 2024-05-30 | 809.52 $ | 33.9% | |
2023-11-22 | 589.01 $ | 2024-02-05 | 698.98 $ | 18.67% | |
2023-11-28 | 585.55 $ | 2024-02-05 | 698.98 $ | 19.37% | |
2024-01-09 | 619.09 $ | 2024-06-06 | 831.6 $ | 34.33% | |
2024-01-16 | 628.08 $ | 2024-02-16 | 775.42 $ | 23.46% | |
2024-01-23 | 623.24 $ | 2024-06-07 | 844.21 $ | 35.45% | |
2024-01-30 | 638.39 $ | 2024-05-21 | 797.71 $ | 24.96% | |
2024-02-06 | 697.82 $ | 2024-06-10 | 859.12 $ | 23.11% |
Eli Lilly and Company (LLY) continues to make waves in the pharmaceutical industry with its innovative and groundbreaking therapies....
Eli Lilly and Company (LLY) has recently made a significant breakthrough in its BRAVE-AA-PEDS study, resulting in a surge of investor attention and market gains....
Eli Lilly and Company (LLY) has been making waves in the pharmaceutical industry with its innovative products and strong performance....
Eli Lilly and Company, a renowned pharmaceutical giant, has recently made a groundbreaking discovery that is set to revolutionize the entire industry....
Eli Lilly and Company (LLY) has been making headlines recently with its groundbreaking research and innovative products....
Eli Lilly and Company (LLY) recently announced the positive outcome of their Phase 3 clinical trial for baricitinib, a drug aimed at treating severe alopecia areata in adolescents....
Eli Lilly and Company (LLY) is set to significantly increase its manufacturing investment in the United States, surpassing a staggering 50 billion since 2020....
Eli Lilly and Company has recently made headlines with its acquisition of Organovos FXR Program, a significant step towards advancing treatment options for Inflammatory Bowel Disease (IBD)....
ELI LILLY AND COMPANY has recently announced the launch of additional Zepbound vial doses, as well as new savings for self-pay patients....
Eli Lilly and Company (LLY) has recently caught the attention of investors as it prepares to participate in the TD Cowens 45th Annual Health Care Conference....